BENLYSTA POWDER FOR SOLUTION

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

BELIMUMAB

Disponibbli minn:

GLAXOSMITHKLINE INC

Kodiċi ATC:

L04AG04

INN (Isem Internazzjonali):

BELIMUMAB

Dożaġġ:

400MG

Għamla farmaċewtika:

POWDER FOR SOLUTION

Kompożizzjoni:

BELIMUMAB 400MG

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

20ML

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

IMMUNOSUPPRESSIVE AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0152941001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2011-07-06

Karatteristiċi tal-prodott

_ _
_ _
_BENLYSTA, Belimumab _
_Page 1 of 66_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
BENLYSTA
Belimumab for injection
120 mg in 5 mL vial lyophilized powder for intravenous infusion
400 mg in 20 mL vial lyophilized powder for intravenous infusion
Belimumab injection
200 mg in 1 mL for subcutaneous injection
Selective Immunosuppressant
GlaxoSmithKline Inc.
100 Milverton Drive
Suite 800
Mississauga, Ontario
L5R 4H1
Date of Initial Authorization:
July 06, 2011
Date of Revision:
March 6, 2024
Submission Control Number: 279901
_©_
_2024 GSK group of companies or its licensor _
_Trademarks are owned by or licensed to the GSK group of companies _
_ _
_ _
_BENLYSTA, Belimumab _
_Page 2 of 66_
RECENT MAJOR LABEL CHANGES
SECTION
DATE
7 WARNINGS AND PRECAUTIONS
10/2023
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
05/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
...................................................................................
4
1.2
Geriatrics
...................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................. 4
4
DOSAGE AND ADMINISTRATION
..................................................................................
5
4.1
Dosing Considerations
............................................................... 5
4.2
Recommended Dose and Dosage Adjustment .......................... 5